Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#131 / 200 Total
ARQT - Arcutis Biotherapeutics Inc - Stock Price Chart
TickerARQT [NASD, RUT]
CompanyArcutis Biotherapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap999.01MEPS (ttm)-2.92
P/E-EPS this Y55.07%
Forward P/E-EPS next Y27.09%
PEG-EPS past 5Y-48.07%
P/S9.39EPS next 5Y9.80%
P/B4.43EPS Q/Q73.03%
Dividend-Sales Q/Q1574.06%
Insider Own21.83%Inst Own98.53%
Insider Trans-0.53%Inst Trans9.75%
Short Float27.23%EarningsMay 14/a
Analyst Recom1.33Target Price19.00
Avg Volume3.20M52W Range1.76 - 13.17
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Welgus Howard G.DirectorJun 04 '24Option Exercise1.6810,00016,806180,200Jun 06 04:15 PM
Welgus Howard G.DirectorJun 04 '24Sale8.0110,00080,092170,200Jun 06 04:15 PM
Burnett PatrickSee RemarksMay 30 '24Option Exercise0.0023,0000232,793May 31 04:50 PM
Burnett PatrickSee RemarksMay 30 '24Sale8.7523,000201,319209,793May 31 04:50 PM
Burnett PatrickSee RemarksMay 29 '24Sale8.7249,952435,387209,793May 31 04:50 PM
AFRM - Affirm Holdings Inc - Stock Price Chart
TickerAFRM [NASD]
CompanyAffirm Holdings Inc
CountryUSA
IndustrySoftware - Infrastructure
Market Cap9.55BEPS (ttm)-2.22
P/E-EPS this Y38.84%
Forward P/E-EPS next Y17.95%
PEG-EPS past 5Y-58.94%
P/S4.53EPS next 5Y-
P/B3.63EPS Q/Q38.09%
Dividend-Sales Q/Q51.23%
Insider Own19.69%Inst Own69.60%
Insider Trans-0.27%Inst Trans4.87%
Short Float10.95%EarningsMay 08/b
Analyst Recom2.90Target Price36.80
Avg Volume6.44M52W Range12.81 - 52.48
Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rabois KeithDirectorJun 03 '24Sale28.839,276267,39982,899Jun 05 04:14 PM
Jiyane SipheleleChief Accounting OfficerJun 01 '24Option Exercise0.0012,8270226,427Jun 03 06:15 PM
Adkins KatherineChief Legal OfficerJun 01 '24Option Exercise0.006,7830112,675Jun 03 06:14 PM
Linford MichaelChief Financial OfficerJun 01 '24Option Exercise0.002,3360118,926Jun 03 06:14 PM
Michalek LiborPresidentJun 01 '24Option Exercise0.002,3360146,542Jun 03 06:15 PM
ALT - Altimmune Inc - Stock Price Chart
TickerALT [NASD, RUT]
CompanyAltimmune Inc
CountryUSA
IndustryBiotechnology
Market Cap433.20MEPS (ttm)-1.59
P/E-EPS this Y7.32%
Forward P/E-EPS next Y-1.28%
PEG-EPS past 5Y35.74%
P/S1056.58EPS next 5Y-
P/B2.50EPS Q/Q13.98%
Dividend-Sales Q/Q-76.19%
Insider Own0.78%Inst Own62.72%
Insider Trans0.00%Inst Trans10.67%
Short Float33.37%EarningsMay 09/b
Analyst Recom1.50Target Price20.57
Avg Volume3.29M52W Range2.09 - 14.84
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Roberts M ScotChief Scientific OfficerFeb 02 '24Option Exercise0.007,775044,990Feb 05 06:02 PM
Harris Matthew ScottChief Medical OfficerFeb 02 '24Option Exercise0.007,775055,965Feb 05 06:01 PM
Garg Vipin KPresident and CEOFeb 02 '24Option Exercise0.0018,9500300,404Feb 05 06:00 PM
Harris Matthew ScottChief Medical OfficerFeb 01 '24Option Exercise0.006,166049,991Feb 05 06:01 PM
Roberts M ScotChief Scientific OfficerFeb 01 '24Option Exercise0.006,166039,016Feb 05 06:02 PM
CENN - Cenntro Inc - Stock Price Chart
TickerCENN [NASD]
CompanyCenntro Inc
CountryUSA
IndustryAuto Manufacturers
Market Cap53.03MEPS (ttm)-0.82
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y58.15%
P/S2.41EPS next 5Y-
P/B0.47EPS Q/Q-731.67%
Dividend-Sales Q/Q-2.26%
Insider Own28.64%Inst Own1.46%
Insider Trans0.00%Inst Trans11.07%
Short Float3.98%Earnings-
Analyst Recom-Target Price-
Avg Volume165.82K52W Range1.00 - 5.00
Cenntro, Inc. is a commercial electric vehicle technology company, which engages in the sale and production of electric vehicles. It provides support to city services, last-mile delivery, and other commercial applications. The company was founded on March 9, 2023 and is headquartered in Freehold, NJ.
XBP - XBP Europe Holdings Inc - Stock Price Chart
TickerXBP [NASD]
CompanyXBP Europe Holdings Inc
CountryUSA
IndustrySoftware - Infrastructure
Market Cap37.11MEPS (ttm)-2.69
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q39.15%
Dividend-Sales Q/Q-
Insider Own72.31%Inst Own22.36%
Insider Trans-0.46%Inst Trans-67.81%
Short Float0.23%Earnings-
Analyst Recom-Target Price-
Avg Volume1.29M52W Range1.09 - 47.40
XBP Europe Holdings, Inc. is a pan-European integrator of bills, payments, and related solutions and services seeking to enable digital transformation of businesses. It provides business process management solutions with proprietary software suites and deep domain expertise, serving as a technology and services partner for its clients. The company is headquartered in Irving, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CFAC Holdings VIII, LLC.10% OwnerDec 14 '23Sale11.43100,6761,150,7126,601,904Dec 18 05:58 PM
ACMR - ACM Research Inc - Stock Price Chart
TickerACMR [NASD, RUT]
CompanyACM Research Inc
CountryUSA
IndustrySemiconductor Equipment & Materials
Market Cap1.46BEPS (ttm)1.31
P/E17.94EPS this Y-4.03%
Forward P/E12.61EPS next Y19.36%
PEG0.42EPS past 5Y56.93%
P/S2.30EPS next 5Y42.74%
P/B1.83EPS Q/Q134.79%
Dividend0.74%Sales Q/Q104.95%
Insider Own24.05%Inst Own54.25%
Insider Trans-3.99%Inst Trans-2.83%
Short Float8.32%EarningsMay 08/b
Analyst Recom1.00Target Price37.93
Avg Volume1.29M52W Range11.09 - 34.40
ACM Research, Inc. engages in the development, manufacture, and sale of single-wafer wet cleaning equipment. It supplies process solutions that semi conductor manufacturers can use in numerous manufacturing steps to remove particles, contaminants and other random defects, and thereby improve product yield. The company tools can be used in fabricating foundry, logic and memory chips including dynamic random-access memory, or DRAM, and 3D NAND-flash memory chips. The company was founded by David H. Wang and Hui Wang in January 1998 and is headquartered in Fremont, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wang JianSee remarksJun 11 '24Option Exercise4.6230,000138,600283,158Jun 12 04:30 PM
Wang JianSee remarksJun 11 '24Sale23.0230,000690,576253,158Jun 12 04:30 PM
Wang JianSee remarksJun 10 '24Option Exercise4.6230,000138,600283,158Jun 12 04:30 PM
Wang JianSee remarksJun 10 '24Sale22.0730,000662,100253,158Jun 12 04:30 PM
Wang JianSee remarksJun 07 '24Option Exercise4.6230,000138,600283,158Jun 07 09:32 PM
UPC - Universe Pharmaceuticals INC - Stock Price Chart
TickerUPC [NASD]
CompanyUniverse Pharmaceuticals INC
CountryChina
IndustryDrug Manufacturers - Specialty & Generic
Market Cap8.10MEPS (ttm)-1.70
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S0.25EPS next 5Y-
P/B0.20EPS Q/Q47.96%
Dividend-Sales Q/Q-13.17%
Insider Own57.05%Inst Own0.04%
Insider Trans0.00%Inst Trans-97.04%
Short Float1.25%EarningsJan 30/a
Analyst Recom-Target Price-
Avg Volume77.41K52W Range0.75 - 5.53
Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.
MGX - Metagenomi Inc. - Stock Price Chart
TickerMGX [NASD]
CompanyMetagenomi Inc.
CountryUSA
IndustryBiotechnology
Market Cap207.90MEPS (ttm)-
P/E-EPS this Y83.80%
Forward P/E-EPS next Y1.98%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B0.75EPS Q/Q-329.49%
Dividend-Sales Q/Q127.13%
Insider Own50.36%Inst Own28.37%
Insider Trans5.01%Inst Trans-
Short Float0.36%EarningsMay 14/a
Analyst Recom1.29Target Price16.83
Avg Volume104.27K52W Range5.50 - 12.74
Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit-ing toolbox, ther-a-peu-tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novo Holdings A/S10% OwnerFeb 13 '24Buy15.00800,00012,000,0001,739,175Feb 15 08:38 PM
Novo Holdings A/S10% OwnerFeb 09 '24Buy10.25100,0001,025,000100,000Feb 15 08:38 PM
NCLH - Norwegian Cruise Line Holdings Ltd - Stock Price Chart
TickerNCLH [NYSE, S&P 500]
CompanyNorwegian Cruise Line Holdings Ltd
CountryUSA
IndustryTravel Services
Market Cap7.10BEPS (ttm)0.65
P/E25.37EPS this Y104.79%
Forward P/E9.01EPS next Y28.23%
PEG0.52EPS past 5Y-38.02%
P/S0.80EPS next 5Y49.20%
P/B19.62EPS Q/Q110.69%
Dividend-Sales Q/Q20.27%
Insider Own1.06%Inst Own59.30%
Insider Trans-0.14%Inst Trans-1.25%
Short Float5.86%EarningsMay 01/b
Analyst Recom2.38Target Price20.88
Avg Volume13.26M52W Range12.70 - 22.75
Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ashby Faye L.SVP & Chief Accounting OfficerJun 05 '24Sale18.4219,582360,614163,579Jun 06 04:15 PM
Byng-Thorne ZillahDirectorMay 31 '24Buy16.5013,360220,44013,360Jun 03 04:15 PM
Cil Jose E.DirectorMay 22 '24Buy16.3820,000327,50040,000May 23 04:16 PM
Kempa MarkEVP & CFOMar 08 '24Sale20.0119,965399,532268,386Mar 11 04:30 PM
ALLO - Allogene Therapeutics Inc - Stock Price Chart
TickerALLO [NASD, RUT]
CompanyAllogene Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap490.63MEPS (ttm)-1.79
P/E-EPS this Y28.35%
Forward P/E-EPS next Y-3.24%
PEG-EPS past 5Y22.18%
P/S3774.10EPS next 5Y1.00%
P/B0.87EPS Q/Q43.72%
Dividend-Sales Q/Q-57.69%
Insider Own34.49%Inst Own50.59%
Insider Trans2.41%Inst Trans4.07%
Short Float29.68%EarningsMay 13/a
Analyst Recom1.61Target Price11.76
Avg Volume2.48M52W Range2.23 - 6.05
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Humer Franz BDirectorMay 30 '24Sale2.3411,20026,181255,253Jun 03 04:09 PM
Belldegrun ArieDirectorMay 16 '24Buy2.901,724,1374,999,9971,724,137May 20 09:33 PM
Parker Geoffrey M.CHIEF FINANCIAL OFFICERJan 30 '24Buy3.60190683819,590Mar 06 09:52 PM
MESSEMER DEBORAH M.DirectorDec 18 '23Sale2.7018,64050,31762,456Dec 20 04:26 PM
Mayo StephenDirectorAug 07 '23Sale4.2910,00042,85525,328Aug 09 04:07 PM
191011121314151617181920